Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 232

1.

Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.

Jabbari S, Weinberg VK, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):36-42. doi: 10.1016/j.ijrobp.2009.01.029.

PMID:
19409729
2.

Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.

Fukunaga-Johnson N, Sandler HM, McLaughlin PW, Strawderman MS, Grijalva KH, Kish KE, Lichter AS.

Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):311-7.

PMID:
9226317
3.

Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer.

Pinover WH, Hanlon AL, Horwitz EM, Hanks GE.

Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):649-54.

PMID:
10837947
4.

Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.

Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):888-92.

PMID:
11958880
5.

[Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].

Geinitz H, Zimmermann F, von Wedel E, Thamm R, Busch R, Feldmann HJ, Molls M.

Strahlenther Onkol. 2002 Jul;178(7):369-77. German.

PMID:
12163991
6.

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.

Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.

Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52.

PMID:
10802358
7.

Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level.

Pickett B, Kurhanewicz J, Pouliot J, Weinberg V, Shinohara K, Coakley F, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):65-72. Epub 2006 Mar 6.

PMID:
16517094
8.

Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison.

Perez CA, Michalski JM, Purdy JA, Wasserman TH, Williams K, Lockett MA.

Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):629-37.

PMID:
10837945
9.
10.

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.

Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA.

J Clin Oncol. 1999 Feb;17(2):517-22.

PMID:
10080594
11.

The impact of irregularly rising prostate-specific antigen and "impending failure" on the apparent outcome of localized prostate cancer following radiotherapy.

Hodgson DC, Catton CN, Warde P, Gospodarowicz MK, Milosevic MF, McLean M B M, Catton P.

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):957-63.

PMID:
11240236
12.

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.

Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M 3rd, Gottschalk A.

Radiat Oncol. 2014 Feb 2;9:42. doi: 10.1186/1748-717X-9-42.

13.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
14.

Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.

Perez CA, Michalski JM, Mansur D, Lockett MA.

Clin Prostate Cancer. 2002 Sep;1(2):97-104.

PMID:
15046700
15.

Dose selection for prostate cancer patients based on dose comparison and dose response studies.

Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T.

Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):823-32.

PMID:
10705002
16.

Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.

Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M 3rd, Gottschalk AR.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34. doi: 10.1016/j.ijrobp.2010.10.026. Epub 2010 Dec 22.

PMID:
21183287
17.

A systematic overview of radiation therapy effects in prostate cancer.

Nilsson S, Norlén BJ, Widmark A.

Acta Oncol. 2004;43(4):316-81. Review.

PMID:
15303499
19.

Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.

Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, Spencer W, Stromberg J, Huang R, Vicini F.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27.

PMID:
12023135
20.

Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis.

Coen JJ, Zietman AL, Rossi CJ, Grocela JA, Efstathiou JA, Yan Y, Shipley WU.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e25-31. doi: 10.1016/j.ijrobp.2011.01.039. Epub 2011 Apr 4.

PMID:
21470787

Supplemental Content

Support Center